1985 Fiscal Year Final Research Report Summary
Immunological studies on Kawasaki disease
| Project/Area Number |
59440089
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
KANO Kyoichi 東京大学, 医科研, 教授 (80152825)
|
|---|
| Project Period (FY) |
1984 – 1985
|
| Keywords | Kawasaki disease / H-D antibody / immune complex / Immuno suppressive factor / モノクローナル抗体 |
|---|
| Research Abstract |
To investigate immunopathological mechanisms involved in Kawasaki Disease (febrile mucocutaeneous lymph node syndrome, MCLS), sequential sera of 56 MCLS patients, age 6 Mo-3 yrs) were studied for heterophile antibodies and immune complexes (IC). EIA with purified high molecular glycoprotein (HMWGP) of bovine erythrocytes demonstrated the presence of HanganutziuDeicher (H-D) antibodies of IgM (43%) and IgE(49%) classes. The immunodominant group of HMWGP recognized by the MCLS sera was identified as N-glycolyl neuraminic acid (NGNA). Some of the H-D antibodies were directed to asialo HMWGP. IC was detected by anti-antibody inhibition in 23% of the sera.
Acute phase sera were shown to contain an inhibitory factor against proliferative response of normal peripheral blood mononuclear cells (PBM) stimulated by mitogens and allogeneic PBM. The inhibitory factor was purified by ion exchange chromatography, gel filtration and HPLC and identified as 140 KD protein by Western blot analysis by using murine monoclonal antibodies. Similar analysis of the MCLS sera demonstrated the presence of the 140 KD protein in 80% of acute phase sera.
In an attempt to develop an immunodiagnostic procedure for MCLS an EIA sandwich procedure was established by using human H-D antibodies of IgG class and chicken anti-NGNA antibodies. Results of preliminary experiments indicated that this procedure can detect H-D antigen in the patient's serum as low as 100 ng/ml. Clinical trials are now underway.
|
